The drug simeprevir (trade name: Olysio) has been available since May 2014 for the treatment of adult patients with chronic hepatitis C infection. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in…
Hepatitis C in the News Your source for hepatitis C-related news from around the web.
Not sure what to submit? Read our news guidelines first.
Hepatology | The World Hepatitis Alliance has created HCV Quest, a global survey that provides a forum for patients with hepatitis C virus, according to an announcement on the European Association for the Study of the Liver website.
Eliminating hepatitis C virus infection is feasible, can provide economic benefits, enhance capacity to address other health challenges, and improve health care disparities, an expert argues. More than 185 million people worldwide, 3 percent of the world's population, are living with HCV and 350,000 die each year.
In this downloadable slideset, Jordan J. Feld MD, MPH, Paul Y. Kwo, MD, and Stefan Zeuzem, MD, review key studies on the treatment of hepatitis C presented at the 2014 Annual Meeting of the European Association for the Study of the Liver.
Belt was, many years ago, an intravenous drug user, which is almost certainly how she contracted hepatitis C. Now clean and sober for more than two decades, happily married and a devoted mother and grandmother, she's glad to rid herself of the last vestige of that lifestyle. […]
— Broader organ sharing in U.S. will result in more air travel, researchers say.
All over the country, state governments are grappling with the same question: "What do we do about Sovaldi?" The drug seems to be far more effective than alternatives at treating hepatitis C, a disease that, left untreated, frequently progresses to liver disease and then death. It also costs $84,000 for…
Infectious Disease | Novel direct-acting antiviral agents were effective in treating infection with hepatitis C virus genotype 1 - even in the hardest-to-treat patients - according to results from two major clinical trials published in the Lancet.
Significant gaps in hepatitis C care identified in a new meta-analysis will prove useful as the U.S. health care system continues to see an influx of patients with the disease because of improved screening efforts and new, promising drugs.
Hepatitis C is a disease that is caused by a virus that affects the liver. Even though the disease often doesn't produce symptoms, it can seriously damage the liver and can be fatal. An estimated 3.2 million Americans have Hepatitis C.